Chongqing Lummy Pharmaceutical Gestione

Gestione criteri di controllo 3/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Rongzhao Qiu

Amministratore delegato

CN¥830.8k

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	4.4yrs
Proprietà del CEO	n/a
Durata media del management	5.5yrs
Durata media del Consiglio di amministrazione	4.4yrs

Aggiornamenti recenti sulla gestione

Recent updates

Subdued Growth No Barrier To Chongqing Lummy Pharmaceutical Co., Ltd. (SZSE:300006) With Shares Advancing 32%

Nov 15

We Think Chongqing Lummy Pharmaceutical's (SZSE:300006) Healthy Earnings Might Be Conservative

Oct 29

Revenues Not Telling The Story For Chongqing Lummy Pharmaceutical Co., Ltd. (SZSE:300006) After Shares Rise 36%

Oct 01

What Chongqing Lummy Pharmaceutical Co., Ltd.'s (SZSE:300006) 36% Share Price Gain Is Not Telling You

Oct 01

Risks To Shareholder Returns Are Elevated At These Prices For Chongqing Lummy Pharmaceutical Co., Ltd. (SZSE:300006)

Feb 27

AMMINISTRATORE DELEGATO

Rongzhao Qiu (30 yo)

4.4yrs

Mandato

CN¥830,800

Compensazione

Mr. Rongzhao Qiu is General Manager of Chongqing Lummy Pharmaceutical Co., Ltd. from June 12, 2020.

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Rongzhao Qiu	General Manager	4.4yrs	CN¥830.80k	Nessun dato
Xue Feng Leng	Deputy General Manager and Vice Chairman	8.7yrs	CN¥867.50k	Nessun dato
Wen Lai	Financial Director	8.7yrs	CN¥678.40k	Nessun dato
Song Lin	Deputy GM & Director	1.9yrs	CN¥410.20k	Nessun dato
Dan Cui	Deputy GM	6.7yrs	CN¥359.70k	0.0016% CN¥ 81.9k

5.5yrs

Durata media

50yo

Età media

Gestione esperta: Il team dirigenziale di 300006 è esperto e expertise (durata media dell'incarico 5.5 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Xue Feng Leng	Deputy General Manager and Vice Chairman	8.7yrs	CN¥867.50k	Nessun dato
Song Lin	Deputy GM & Director	1.8yrs	CN¥410.20k	Nessun dato
Yuan Yuan	Chairman of Supervisory Board	7.8yrs	Nessun dato	Nessun dato
Xujiang Chen	Independent Director	4.4yrs	CN¥88.50k	Nessun dato
Geng Chen	Independent Director	4.4yrs	CN¥88.50k	Nessun dato
Jiansheng Liang	Chairman	2.9yrs	CN¥729.40k	Nessun dato
Rihua Ou	Director	4.4yrs	Nessun dato	Nessun dato
Weiyan Tang	Director	4.4yrs	Nessun dato	Nessun dato
Changbi Li	Independent Director	4.4yrs	CN¥88.50k	Nessun dato
Huichuan Xu	Employee Supervisor	10.8yrs	Nessun dato	Nessun dato
Mingyue Tan	Supervisor	2.9yrs	Nessun dato	Nessun dato
Hai Run Wang	Director	1.8yrs	Nessun dato	Nessun dato

4.4yrs

Durata media

47yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di 300006 sono considerati esperti (durata media dell'incarico 4.4 anni).

Chongqing Lummy Pharmaceutical Gestione

Gestione criteri di controllo 3/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Chongqing Lummy Pharmaceutical Co., Ltd., Annual General Meeting, Apr 12, 2024

Less than half of directors are independent

Insufficient new directors

Chongqing Lummy Pharmaceutical Co., Ltd., Annual General Meeting, Apr 15, 2022

Chongqing Lummy Pharmaceutical Co., Ltd., Annual General Meeting, Apr 15, 2022

Recent updates

Subdued Growth No Barrier To Chongqing Lummy Pharmaceutical Co., Ltd. (SZSE:300006) With Shares Advancing 32%

We Think Chongqing Lummy Pharmaceutical's (SZSE:300006) Healthy Earnings Might Be Conservative

Third quarter 2024 earnings released: CN¥0.025 loss per share (vs CN¥0 in 3Q 2023)

Revenues Not Telling The Story For Chongqing Lummy Pharmaceutical Co., Ltd. (SZSE:300006) After Shares Rise 36%

What Chongqing Lummy Pharmaceutical Co., Ltd.'s (SZSE:300006) 36% Share Price Gain Is Not Telling You

Chongqing Lummy Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Oct 23, 2024

New minor risk - Share price stability

Investor sentiment improves as stock rises 19%

Second quarter 2024 earnings released: EPS: CN¥0.006 (vs CN¥0.048 loss in 2Q 2023)

Chongqing Lummy Pharmaceutical Co., Ltd. to Report First Half, 2024 Results on Aug 24, 2024

First quarter 2024 earnings released: CN¥0.004 loss per share (vs CN¥0.003 loss in 1Q 2023)

First quarter 2024 earnings released: CN¥0.004 loss per share (vs CN¥0.003 loss in 1Q 2023)

First quarter 2024 earnings released: CN¥0.004 loss per share (vs CN¥0.003 loss in 1Q 2023)

First quarter 2024 earnings released: CN¥0.004 loss per share (vs CN¥0.003 loss in 1Q 2023)

First quarter 2024 earnings released: CN¥0.004 loss per share (vs CN¥0.003 loss in 1Q 2023)

First quarter 2024 earnings released: CN¥0.004 loss per share (vs CN¥0.003 loss in 1Q 2023)

First quarter 2024 earnings released: CN¥0.004 loss per share (vs CN¥0.003 loss in 1Q 2023)

Chongqing Lummy Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Apr 24, 2024

Chongqing Lummy Pharmaceutical Co., Ltd., Annual General Meeting, Apr 12, 2024

Full year 2023 earnings released: CN¥0.008 loss per share (vs CN¥0.065 loss in FY 2022)

Risks To Shareholder Returns Are Elevated At These Prices For Chongqing Lummy Pharmaceutical Co., Ltd. (SZSE:300006)

Chongqing Lummy Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Mar 23, 2024

Less than half of directors are independent

Third quarter 2023 earnings released: EPS: CN¥0 (vs CN¥0.011 in 3Q 2022)

Second quarter 2023 earnings released: CN¥0.048 loss per share (vs CN¥0.021 loss in 2Q 2022)

Full year 2022 earnings released: CN¥0.065 loss per share (vs CN¥0.10 loss in FY 2021)

Third quarter 2022 earnings released: EPS: CN¥0.011 (vs CN¥0.012 loss in 3Q 2021)

Second quarter 2022 earnings released: CN¥0.021 loss per share (vs CN¥0.017 loss in 2Q 2021)

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Insufficient new directors

Chongqing Lummy Pharmaceutical Co., Ltd., Annual General Meeting, Apr 15, 2022

Chongqing Lummy Pharmaceutical Co., Ltd., Annual General Meeting, Apr 15, 2022

Full year 2021 earnings: EPS and revenues miss analyst expectations

First quarter 2021 earnings released: EPS CN¥0.055 (vs CN¥0.01 loss in 1Q 2020)

Full year 2020 earnings released: CN¥0.40 loss per share (vs CN¥0.19 loss in FY 2019)

Changzhou Lummy Qingfeng Pharmaceutical Industry Investment Center (Limited Partnership) agreed to acquire 35% Chengdu Medicom Medical Information Systems Co., Ltd from Chongqing Lummy Pharmaceutical Co., Ltd. (SZSE:300006) for approximately CNY 200 million.

Chongqing Lummy Pharmaceutical Co., Ltd. to Report Fiscal Year 2020 Results on Mar 31, 2021

New 90-day low: CN¥6.65

Hangzhou Bulaisen Pharmaceutical Technology Co., Ltd. signed a share transfer agreement to acquire Sichuan Hezheng Pharmaceutical Co., Ltd. from Chongqing Lummy Pharmaceutical Co., Ltd. (SZSE:300006) for approximately CNY 170 million.

New 90-day low: CN¥7.08

New 90-day high: CN¥8.54

New 90-day high: CN¥8.21

Third quarter earnings released

Chongqing Lummy Pharmaceutical Co., Ltd. to Report Q3, 2020 Results on Oct 28, 2020

First half earnings released

AMMINISTRATORE DELEGATO

Mandato

Compensazione

Gruppo dirigente

Durata media

Età media

Membri del Consiglio di amministrazione

Durata media

Età media